Revenue and net profit declined sharply year-over-year due to the disposal of key subsidiaries, but the blood products segment showed resilience with slight growth. Strategic acquisitions, new plasma station licenses, and smart factory investments position the company for future expansion.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.